Ovation.io, a leading human omics and clinical data company, and PrecisionLife, a precision medicine firm transforming the understanding and management of complex chronic diseases, have announced a collaboration to develop biomarkers that predict patient response to glucagon-like peptide-1 receptor agonist therapies. The partnership aims to create a payor-focused test that can guide reimbursement decisions based on a patient’s likelihood to safely and effectively respond to GLP-1 therapies in specific clinical indications. Ovation contributes its longitudinal multiomic data from 25,000 U.S. patients treated with GLP-1s, while PrecisionLife brings its AI-driven combinatorial analytics platform capable of revealing the underlying drivers of disease and identifying patients most likely to benefit from particular therapies.
Health Technology Insights: TurnOnGreen to Power New High-Precision Medical Laser
This first-of-its-kind initiative will investigate the biological mechanisms behind individual variation in GLP-1 response and identify biomarkers linked to safety, efficacy, and tolerability. The ultimate goal is to help payors and healthcare providers optimize outcomes, reduce unnecessary clinical interventions, improve patient access, and support sustainable healthcare budgets amid rising demand. Additionally, the insights could assist biopharma companies in launching new GLP-1 products in indications that currently lack reimbursement.
Health Technology Insights: Lipocine Reports Positive Phase 3 Safety for LPCN 1154
GLP-1 therapies represent one of the fastest-growing drug classes globally, projected to drive a 95-billion-dollar obesity market by 2030 according to Goldman Sachs Research. In the U.S. alone, it is estimated that 30 to 70 million prescriptions will be written annually by the end of the decade. However, their high cost and variable patient response create significant challenges for payors, making precise targeting of these therapies essential to avoid unsustainable budget pressures.
Curt Medeiros, Chief Executive Officer of Ovation.io, said the project demonstrates a sustainable approach to using GLP-1 receptor agonists and highlights Ovation’s ability to provide solutions in high-value disease states where precision medicine can address unmet needs. He emphasized that combining Ovation’s extensive longitudinal omics and clinical data with PrecisionLife’s advanced analytics will generate real-world evidence to guide payors toward smarter reimbursement policies that improve patient outcomes while controlling costs. He also noted that Ovation’s biobank, representative of both sex and ethnicity across the U.S., is scaling rapidly in complex chronic diseases.
Steve Gardner, Chief Executive Officer of PrecisionLife, added that this collaboration provides access to world-class multiomic and clinical data, allowing the company to extend its capability in identifying drug-response biomarkers beyond clinical trials into real-world healthcare. He explained that understanding why some patients respond well to GLP-1 therapies while others do not enables payors to make more informed coverage decisions, helps pharma bring new products to market, and ultimately delivers better value for patients, providers, and the healthcare system. As GLP-1 therapies expand into secondary indications including cardiovascular, kidney, liver, and neurological diseases, the ability to predict drug response becomes increasingly important to optimize resource allocation, expand appropriate therapy use, and support sustainable healthcare delivery.
Health Technology Insights: InteliChart Launches InteliSense to Power a New Era of Patient Engagement
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
